Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Trillium Therapeutics Announces Data Presentations at Upcoming Scientific Meetings


Posted on: 12 Sep 18
  • Updated safety and efficacy data from the TTI-621 intravenous trial at the 16th Annual Discovery on Target Conference
  • Updated data from the TTI-621 intralesional trial in patients with mycosis fungoides and Sézary Syndrome at the EORTC CLTF 2018 Meeting

TORONTO, Sept. 12, 2018 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (Nasdaq:TRIL) (TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that the company is scheduled to present an update on the company’s TTI-621 clinical programs at two upcoming scientific conferences.

16th Annual Discovery on Target - Targeting Tumor Myeloid Cells:

Title:
Presenter:
Date and Time:
Location:
Blocking the CD47 “Do Not Eat” Signal with SIRPaFc Fusion Proteins
Dr. Robert Uger, Chief Scientific Officer
Sept. 28, 2018, 10:45 a.m. ET
Sheraton Boston, Boston, MA
  

EORTC CLTF 2018 Meeting Cutaneous Lymphoma:

Title:Intralesional Injection of the CD47-blocking Immune Checkpoint Inhibitor TTI-621 (SIRPaFc) Induces Antitumor Activity in Patients with Relapsed/Refractory Mycosis Fungoides and Sézary Syndrome: Interim Results of a Multicenter Phase 1 Trial
Presenter:Dr. Christiane Querfeld, City of Hope Cancer Center & Beckman Research Institute
Presentation number:093
Session:Oral presentation, Session 7 / Treatment and clinical aspects 
Date and Time:Sept. 28, 2018, 5:10 p.m. – 6:10 p.m. CEST
Location:Olma Messen Hall 9.2, St. Gallen, Switzerland
  

About Trillium Therapeutics

Trillium is an immuno-oncology company developing innovative therapies for the treatment of cancer. The company’s two clinical programs, TTI-621 and TTI-622, target CD47, a “do not eat” signal that cancer cells frequently use to evade the immune system. Trillium also has a proprietary fluorine-based medicinal chemistry platform that is being used to develop novel compounds directed at undisclosed immuno-oncology targets. For more information, please visit www.trilliumtherapeutics.com

Contact:
James Parsons
Chief Financial Officer
Trillium Therapeutics Inc.
416-595-0627 x232
james@trilliumtherapeutics.com

Investor and Media Relations:
Jessica Tieszen
Canale Communications for Trillium Therapeutics
619-849-5385
jessica@canalecomm.com

GlobeNewswire
globenewswire.com

Last updated on: 12/09/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.